{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:23:08Z","timestamp":1773872588621,"version":"3.50.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014452","name":"University of Cincinnati College of Medicine","doi-asserted-by":"publisher","award":["UG1DA013732"],"award-info":[{"award-number":["UG1DA013732"]}],"id":[{"id":"10.13039\/100014452","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006732","name":"New York University","doi-asserted-by":"publisher","award":["UG1DA013035"],"award-info":[{"award-number":["UG1DA013035"]}],"id":[{"id":"10.13039\/100006732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.jsat.2021.108489","type":"journal-article","created":{"date-parts":[[2021,5,21]],"date-time":"2021-05-21T14:54:23Z","timestamp":1621608863000},"page":"108489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network"],"prefix":"10.1016","volume":"130","author":[{"given":"LaTrice","family":"Montgomery","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Winhusen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Scodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Pavlicova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylanne","family":"Twitty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aimee N.C.","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"An Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward V.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Rotrosen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2021.108489_bb0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2018.12.012","article-title":"Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment","volume":"197","author":"Baldassarri","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108489_bb0010","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1465-3362.2011.00408.x","article-title":"Smoking cessation among Australian methadone clients: Prevalence, characteristics and a need for action","volume":"31","author":"Bowman","year":"2012","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.jsat.2021.108489_bb0015","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S0022-3565(25)21845-6","article-title":"Effects of methadone on human cigarette smoking and subjective ratings","volume":"229","author":"Chait","year":"1984","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.jsat.2021.108489_bb0020","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/ntr\/nts274","article-title":"A comparison of cigarette smoking profiles in opioid-dependent pregnant patients receiving methadone or buprenorphine","volume":"15","author":"Chisolm","year":"2013","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.jsat.2021.108489_bb0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0376-8716(96)01331-2","article-title":"Smoking habits and attitudes in a methadone maintenance treatment population","volume":"44","author":"Clemmey","year":"1997","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108489_bb0030","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/ntr\/ntx189","article-title":"Pilot study of a tailored smoking cessation intervention for individuals in treatment for opioid dependence","volume":"20","author":"Cooperman","year":"2018","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.jsat.2021.108489_bb0035","article-title":"Opioid antagonists for smoking cessation","volume":"6","author":"David","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1016\/j.jsat.2021.108489_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-015889","article-title":"Factors associated with nicotine dependence during methadone maintenance treatment: Findings from a multisite survey in Vietnam","volume":"7","author":"Do","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jsat.2021.108489_bb0045","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pbb.2003.09.017","article-title":"Naltrexone attenuates acute cigarette smoking behavior","volume":"77","author":"Epstein","year":"2004","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.jsat.2021.108489_bb0050","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1037\/1064-1297.8.1.97","article-title":"Associations between tobacco smoking and illicit drug use among methadone-maintained opiate-dependent individuals","volume":"8","author":"Frosch","year":"2000","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2021.108489_bb0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.drugalcdep.2017.05.020","article-title":"Nicotine biomarkers and rate of nicotine metabolism among cigarette smokers taking buprenorphine for opioid dependency","volume":"178","author":"Gubner","year":"2017","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108489_bb0060","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/add.13099","article-title":"An international systematic review of smoking prevalence in addiction treatment","volume":"111","author":"Guydish","year":"2016","journal-title":"Addiction."},{"key":"10.1016\/j.jsat.2021.108489_bb0065","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/ntr\/ntx113","article-title":"Cigarette smoking cessation intervention for buprenorphine treatment patients","volume":"20","author":"Hall","year":"2018","journal-title":"Nicotine & Tobacco Research"},{"key":"10.1016\/j.jsat.2021.108489_bb0075","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1006\/pmed.1994.1009","article-title":"Tobacco use as a distal predictor of mortality among long-term narcotics addicts","volume":"23","author":"Hser","year":"1994","journal-title":"Preventive Medicine"},{"key":"10.1016\/j.jsat.2021.108489_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2016.08.003","article-title":"Nicotine enhancement and reinforcer devaluation: Interaction with opioid receptors","volume":"150","author":"Kirshenbaum","year":"2016","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.jsat.2021.108489_bb0095","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.cct.2016.08.004","article-title":"NIDA clinical trials network CTN-0051, extended-release naltrexone vs. buprenorphine for opioid treatment (X:BOT): Study design and rationale","volume":"50","author":"Lee","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.jsat.2021.108489_bb0100","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicenter, open-label, randomized controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.jsat.2021.108489_bb0110","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF00427902","article-title":"Buprenorphine effects on cigarette smoking","volume":"86","author":"Mello","year":"1985","journal-title":"Psychopharm."},{"key":"10.1016\/j.jsat.2021.108489_bb6005","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1111\/add.12631","article-title":"Varenicline efficacy and safety among methadone-maintained smokers: A randomized placebo-controlled trial","volume":"109","author":"Navhi","year":"2014","journal-title":"Addiction"},{"key":"10.1016\/j.jsat.2021.108489_bb0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cct.2016.09.006","article-title":"Ethical and clinical safety considerations in the design of the effectiveness trial: A comparison of buprenorphine versus naltrexone treatment for opioid dependence","volume":"51","author":"Nunes","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.jsat.2021.108489_bb0130","doi-asserted-by":"crossref","first-page":"932","DOI":"10.3390\/ijerph9030932","article-title":"Tobacco addiction and smoking status in heroin addicts under methadone vs. buprenorphine therapy","volume":"9","author":"Pajusco","year":"2012","journal-title":"International Journal of Environmental Research and Public Health"},{"key":"10.1016\/j.jsat.2021.108489_bb0140","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.addbeh.2014.04.023","article-title":"Spontaneous reductions in smoking during double-blind buprenorphine detoxification","volume":"39","author":"Patrick","year":"2014","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2021.108489_bb0145","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.addbeh.2018.11.043","article-title":"Association between tobacco smoking and opioid use: A meta-analysis","volume":"92","author":"Rajabi","year":"2019","journal-title":"Addictive Behaviors"},{"key":"10.1016\/j.jsat.2021.108489_bb0150","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jsat.2007.08.010","article-title":"Smoking cessation treatment in community-based substance abuse rehabilitation programs","volume":"35","author":"Reid","year":"2008","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2021.108489_bb0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12918-015-0167-x","article-title":"Gene network analysis shows immune-signaling and ERK1\/2 as novel genetic markers for multiple addiction phenotypes: Alcohol, smoking and opioid addiction","volume":"9","author":"Reyes-Gibby","year":"2015","journal-title":"BMC Systems Biology"},{"key":"10.1016\/j.jsat.2021.108489_bb0160","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.drugalcdep.2013.07.005","article-title":"Varenicline for smoking cessation among methadone-maintained smokers: A randomized clinical trial","volume":"133","author":"Stein","year":"2013","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2021.108489_bb0165","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.bcp.2015.07.031","article-title":"Methadone\u2019s effect on nAChRs\u2014A link between methadone use and smoking?","volume":"97","author":"Talka","year":"2015","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.jsat.2021.108489_bb0170","first-page":"1","article-title":"Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder","author":"Wang","year":"2020","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.jsat.2021.108489_bb6000","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/nur.4770130405","article-title":"A critical review of visual analogue scales in the measurement of clinical phenomena","volume":"13","author":"Wewers","year":"1990","journal-title":"Research in Nursing & Health"},{"key":"10.1016\/j.jsat.2021.108489_bb0175","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s002130050756","article-title":"Naltrexone administration affects ad libitum smoking behavior","volume":"140","author":"Wewers","year":"1998","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.jsat.2021.108489_bb0185","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.cct.2016.02.008","article-title":"Design considerations for a pilot trial using a novel approach for evaluating smoking-cessation medication in methadone-maintained smokers","volume":"47","author":"Winhusen","year":"2016","journal-title":"Contemporary Clinical Trials"},{"key":"10.1016\/j.jsat.2021.108489_bb0190","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/15360288.2015.1063559","article-title":"Opioid analgesics and nicotine: More than blowing smoke","volume":"29","author":"Yoon","year":"2015","journal-title":"Journal of Pain & Palliative Care Pharmacotherapy"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002154?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547221002154?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:55:12Z","timestamp":1760039712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547221002154"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"alternative-id":["S0740547221002154"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108489","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2021.108489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108489"}}